BS01 gene therapy for dry age-related macular degeneration
Part of Eyes & vision clinical trials.
This trial tests a new gene therapy, BS01, given as an eye injection. It is for people with advanced dry age-related macular degeneration (AMD) that has caused geographic atrophy—damage to the central part of the retina. The study aims to see if the treatment is safe and can help slow vision loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 85 years old.
- You have geographic atrophy (a type of advanced dry AMD) that affects the center of your vision.
- The damaged area in your eye must be a certain size—between about 2 and 7 times the size of a standard disc in your retina.
- Your vision in the study eye is between 20/50 and 20/400 (meaning you can read the large letter on an eye chart but not the smaller ones).
- You have not had any previous gene therapy or radiation around the eye.
- You have not had eye surgery in the last 3 months, and you do not have any eye infections or certain other eye conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental gene therapy, OCU410, for people with geographic atrophy, an advanced form of dry AMD that causes blind spots in the center of vision. The study aims to see if this treatment can slow down the progression of the disease and help preserve remaining vision.
This trial tests a new treatment called PST-611, a non-viral gene therapy given as an injection into the eye. It is for people aged 65 and older with a specific type of advanced dry age-related macular degeneration (AMD) called geographic atrophy, which has been getting worse over the past year.
This trial is testing a new eye implant (TO-O-1007) to see if it's safe and helps slow vision loss from geographic atrophy, a late stage of dry age-related macular degeneration (AMD). The implant is placed inside the eye and releases medicine over time.
This trial tests an oral medication called BRX011 for people with geographic atrophy (a form of advanced dry age-related macular degeneration). The goal is to see if it is safe and can help slow vision loss.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
This trial tests a single gene therapy injection (AGX-08) for people with advanced geographic atrophy, a severe form of age-related macular degeneration that causes vision loss. It aims to see if the treatment is safe and can slow down further damage.
Hear when a new Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.